Inhibition of matrix metalloproteinase activity by ACE inhibitors prevents left ventricular remodeling in a rat model of heart failure.

Angiotensin-converting enzyme (ACE) inhibitors represent the front-line pharmacological treatment of heart failure, which is characterized by left ventricular (LV) dilatation and inappropriate hypertrophy. The mechanism of action of ACE inhibitors is still unclear, but evidence suggests that they may act by influencing matrix metalloproteinase (MMP) activity. This study sought to determine whether ACE inhibitors can directly regulate MMP activity and whether this results in positive structural and functional adaptations to the heart. To this end, MMP-2 activity in LV tissue extracted from rats with an aortocaval (AV) fistula was assessed by in vitro incubation as well as in vivo treatment with captopril, lisinopril, or quinapril. Furthermore, LV size and function were determined in untreated AV fistula rats, AV fistula rats treated with lisinopril (3, 5, and 8 wk), and age-matched sham-operated controls. In vitro incubation with captopril, lisinopril, or quinapril significantly reduced MMP-2 activity, as did in vivo treatment. This occurred without a reduction in the available pool of MMP-2 protein. Long-term in vivo administration of lisinopril also prevented LV dilatation, attenuated myocardial hypertrophy, and prevented changes in myocardial compliance and contractility. The results herein demonstrate that ACE inhibitors prevent MMP-2 activity and, in so doing, represent a mechanism responsible for preventing the negative structural and functional changes that occur in the rat AV fistula model of heart failure.

[1]  J. S. Janicki,et al.  Cause and effect relationship between myocardial mast cell number and matrix metalloproteinase activity. , 2002, American journal of physiology. Heart and circulatory physiology.

[2]  C. Rossi,et al.  Inhibition of gelatinase A (MMP‐2) by batimastat and captopril reduces tumor growth and lung metastases in mice bearing Lewis lung carcinoma , 1999, International journal of cancer.

[3]  M David Tilson,et al.  The polymorphonuclear leukocyte and the abdominal aortic aneurysm: a neglected cell type and a neglected disease. , 2005, Circulation.

[4]  J. Ornato,et al.  ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult—Summary Article , 2005 .

[5]  J. S. Janicki,et al.  Pharmacologic inhibition of mast cell degranulation prevents left ventricular remodeling induced by chronic volume overload in rats. , 2005, Journal of cardiac failure.

[6]  A. Strongin,et al.  Mechanism Of Cell Surface Activation Of 72-kDa Type IV Collagenase , 1995, The Journal of Biological Chemistry.

[7]  J. S. Janicki,et al.  Cardiac mast cell regulation of matrix metalloproteinase-related ventricular remodeling in chronic pressure or volume overload. , 2006, Cardiovascular research.

[8]  M. Fagerhol,et al.  Calprotectin inhibits matrix metalloproteinases by sequestration of zinc , 2001, Molecular pathology : MP.

[9]  J. S. Janicki,et al.  Temporal evaluation of left ventricular remodeling and function in rats with chronic volume overload. , 1996, The American journal of physiology.

[10]  S. Oparil,et al.  Genetic Variation in Angiotensin-Converting Enzyme Does Not Prevent Development of Cardiac Hypertrophy or Upregulation of Angiotensin II in Response to Aortocaval Fistula , 2001, Circulation.

[11]  R Crowther,et al.  X‐ray structure of a novel matrix metalloproteinase inhibitor complexed to stromelysin , 2001, Protein science : a publication of the Protein Society.

[12]  M. Pfeffer,et al.  Influence of Chronic Captopril Therapy on the Infarcted Left Ventricle of the Rat , 1985, Circulation research.

[13]  T. Kubota,et al.  Captopril inhibits glioma cell invasion in vitro: involvement of matrix metalloproteinases. , 1995, Anticancer research.

[14]  J. S. Janicki,et al.  Cardiac mast cell- and chymase-mediated matrix metalloproteinase activity and left ventricular remodeling in mitral regurgitation in the dog. , 2003, Journal of molecular and cellular cardiology.

[15]  J. Woessner.  The Family of Matrix Metalloproteinasesa , 1994 .

[16]  C. Brinckerhoff,et al.  Using inhibitors of metalloproteinases to treat arthritis. Easier said than done? , 1994, Arthritis and rheumatism.

[17]  J. Woessner,et al.  Remodeling of human myocardial collagen in idiopathic dilated cardiomyopathy. Role of metalloproteinases and pyridinoline cross-links. , 1996, The American journal of pathology.

[18]  K. Lindpaintner,et al.  Angiotensin AT1 receptor inhibition. Effects on hypertrophic remodeling and ACE expression in rats with pressure-overload hypertrophy due to ascending aortic stenosis. , 1997, Circulation.

[19]  Gillian Murphy,et al.  The TIMP2 Membrane Type 1 Metalloproteinase “Receptor” Regulates the Concentration and Efficient Activation of Progelatinase A , 1998, The Journal of Biological Chemistry.

[20]  R. Williams,et al.  Inhibition of matrix metalloproteinase activity and growth of gastric adenocarcinoma cells by an angiotensin converting enzyme inhibitor in in vitro and murine models. , 2005, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[21]  F. Spinale,et al.  Time-dependent changes in matrix metalloproteinase activity and expression during the progression of congestive heart failure: relation to ventricular and myocyte function. , 1998, Circulation research.

[22]  M. Zile,et al.  Angiotensin-converting enzyme and matrix metalloproteinase inhibition with developing heart failure: comparative effects on left ventricular function and geometry. , 1999, The Journal of pharmacology and experimental therapeutics.

[23]  R. Körfer,et al.  Cardiac remodelling in end stage heart failure: upregulation of matrix metalloproteinase (MMP) irrespective of the underlying disease, and evidence for a direct inhibitory effect of ACE inhibitors on MMP , 2002, Heart.

[24]  T. Bocan,et al.  MMP/TIMP expression in spontaneously hypertensive heart failure rats: the effect of ACE- and MMP-inhibition. , 2000, Cardiovascular research.

[25]  Marvin A. Konstam,et al.  Heart Failure Society of America (HFSA) practice guidelines. HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction--pharmacological approaches. , 1999, Journal of cardiac failure.

[26]  T. Haas.  Endothelial cell regulation of matrix metalloproteinases. , 2005, Canadian journal of physiology and pharmacology.

[27]  Y. Itoh,et al.  Steps involved in activation of the complex of pro-matrix metalloproteinase 2 (progelatinase A) and tissue inhibitor of metalloproteinases (TIMP)-2 by 4-aminophenylmercuric acetate. , 1995, The Biochemical journal.

[28]  M. Hori,et al.  Activation of Matrix Metalloproteinases Precedes Left Ventricular Remodeling in Hypertensive Heart Failure Rats: Its Inhibition as a Primary Effect of Angiotensin-Converting Enzyme Inhibitor , 2004, Circulation.

[29]  J. S. Janicki,et al.  Effects of Matrix Metalloproteinase Inhibition on Ventricular Remodeling Due to Volume Overload , 2002, Circulation.

[30]  D. Sorbi,et al.  Captopril inhibits the 72 kDa and 92 kDa matrix metalloproteinases. , 1993, Kidney international.

[31]  D. Levy,et al.  Left ventricular dilatation and the risk of congestive heart failure in people without myocardial infarction. , 1997, The New England journal of medicine.

[32]  A. Turner.  Exploring the structure and function of zinc metallopeptidases: old enzymes and new discoveries. , 2003, Biochemical Society transactions.

[33]  J. S. Janicki,et al.  Cardiac mast cell-mediated activation of gelatinase and alteration of ventricular diastolic function. , 2002, American journal of physiology. Heart and circulatory physiology.

[34]  Z. Galis,et al.  Myocardial matrix metalloproteinase activity and abundance with congestive heart failure. , 1998, American journal of physiology. Heart and circulatory physiology.

[35]  J. Woessner.  The family of matrix metalloproteinases. , 1994, Annals of the New York Academy of Sciences.

[36]  S. Yusuf,et al.  Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. SOLVD Investigators. , 1992, Circulation.

[37]  M. Webb,et al.  Angiotensin-converting enzyme inhibition and angiotensin II subtype-1 receptor blockade during the progression of left ventricular dysfunction: differential effects on myocyte contractile processes. , 1997, The Journal of pharmacology and experimental therapeutics.

[38]  S. Yusuf,et al.  Effects of the Angiotensin Converting Enzyme Inhibitor Enalapril on the Long‐term: Progression of Left Ventricular Dysfunction in Patients With Heart Failure , 1992, Circulation.

[39]  O. Volpert,et al.  Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats. , 1996, The Journal of clinical investigation.

[40]  J. S. Janicki,et al.  Contribution of ventricular remodeling to pathogenesis of heart failure in rats. , 2001, American journal of physiology. Heart and circulatory physiology.

[41]  M. Ruzicka,et al.  Relevance of blockade of cardiac and circulatory angiotensin-converting enzyme for the prevention of volume overload-induced cardiac hypertrophy. , 1995, Circulation.

[42]  N. Borkakoti.  Matrix metalloproteases: variations on a theme. , 1998, Progress in biophysics and molecular biology.

[43]  G. Butler,et al.  The Soluble Catalytic Domain of Membrane Type 1 Matrix Metalloproteinase Cleaves the Propeptide of Progelatinase A and Initiates Autoproteolytic Activation , 1996, The Journal of Biological Chemistry.